

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Chaoju Eye Care Holdings Limited**  
**朝聚眼科醫療控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*  
**(Stock Code: 2219)**

**(1) DISCLOSEABLE TRANSACTIONS**  
**SUBSCRIPTION OF STRUCTURED DEPOSIT PRODUCTS**  
**(2) UTILISATION OF CERTAIN IDLE PROCEEDS RAISED FROM**  
**GLOBAL OFFERING FOR TREASURY MANAGEMENT**

**SUBSCRIPTION OF STRUCTURED DEPOSIT PRODUCTS**

The Board announces that on November 17, 2021, Chaoju Medical Technology (an indirect wholly-owned subsidiary of the Company) subscribed for Structured Deposit Products in the total principal amount of RMB260 million offered by BOC. The Subscriptions are funded by surplus cash of the Group and not by the proceeds from the Global Offering.

**IMPLICATIONS UNDER THE LISTING RULES**

As each of the Structured Deposit Products was subscribed with the same bank within a 12 month period and is of a similar nature, they would be aggregated as if the Subscriptions were one transaction with that bank for the purpose of calculating the relevant percentage ratios pursuant to Rule 14.22 of the Listing Rules. As the highest applicable ratio of the Subscriptions, on an aggregate basis, exceeds 5% but is less than 25%, the Subscriptions constitute discloseable transactions of the Company and are hence subject to the reporting and announcement requirements but are exempted from the circular and Shareholders' approval requirements under Chapter 14 of the Listing Rules.

**UTILISATION OF CERTAIN IDLE PROCEEDS RAISED FROM GLOBAL OFFERING FOR TREASURY MANAGEMENT**

The net proceeds from the Global Offering received by the Company, after deduction of the underwriting fees and commissions and other expenses payable by the Company with the Global Offering, amounted to approximately HK\$1,599 million. As of the date of this announcement, the Group has accumulatively used approximately HK\$102.6 million in accordance with the intended purpose as stated in the Prospectus, and the balance of such proceeds amounts to HK\$1,496.4 million. According to the expected timeline for utilisation of the proceeds from the Global Offering, the Group anticipates no substantial funding would be used in a short period of time and a large amount of proceeds from the Global Offering will be left idle.

With a view to enhancing the utilisation and efficiency of its idle IPO Proceeds, the Company may apply some of the idle IPO Proceeds to further subscribe for low-risk short-term wealth management products issued by reputable commercial banks similar to the Subscriptions in the PRC or Hong Kong in the future, thereby increasing the overall income of the Company while at the same time ensuring that the planned usage of IPO Proceeds will not be affected. The Company will continuously assess the planned usage of IPO Proceeds and publish further announcement(s) in accordance with the requirements of the Listing Rules as and when appropriate.

## SUBSCRIPTION OF STRUCTURED DEPOSIT PRODUCTS

The Board announces that on November 17, 2021, Chaoju Medical Technology (an indirect wholly-owned subsidiary of the Company) subscribed for the Structured Deposit Products in the total principal amount of RMB260 million offered by BOC. The key terms of the Subscriptions are set out in the tables below.

### Structured Deposit Products

#### (I) Structured deposit product (CSDVY202109218)

Date of subscription:	November 17, 2021
Name of the structured deposit product:	BOC Linked Structured Deposit Product (Corporate Client) (中國銀行掛鈎型結構性存款)(機構客戶) (CSDVY202109218)
Parties:	(1) Chaoju Medical Technology; and (2) BOC
Principal amount of subscription:	RMB130,000,000
Term of product:	From November 19, 2021 to February 17, 2022
Type of product and risk rating:	Principal-guaranteed with minimum return guaranteed and is regarded as a low risk product by BOC
Expected rate of investment return:	1.5000% to 4.5492%
Investment scope:	This structured deposit product is linked structural deposit. The linked indicator is USD/EUR exchange rate

(II) Structured deposit product (CSDVY202109219)

Date of subscription:	November 17, 2021
Name of the structured deposit product:	BOC Linked Structured Deposit Product (Corporate Client) (中國銀行掛鈎型結構性存款)(機構客戶) (CSDVY202109219)
Parties:	(1) Chaoju Medical Technology; and (2) BOC
Principal amount of subscription:	RMB130,000,000
Term of product:	From November 19, 2021 to February 18, 2022
Type of product and risk rating:	Principal-guaranteed with minimum return guaranteed and is regarded as a low risk product by BOC
Expected rate of investment return:	1.5100% to 4.5417%
Investment scope:	This structured deposit product is linked structural deposit. The linked indicator is USD/EUR exchange rate

**REASONS FOR AND BENEFITS OF THE SUBSCRIPTIONS**

The Structured Deposit Products are of low risk nature with satisfactory liquidity, and the Subscriptions are carried out by the Company for treasury management purpose in order to maximize its return on the surplus cash received from its business operations. The Subscriptions are funded by surplus cash of the Group and not by the proceeds from the Global Offering. The Group expects that the Structured Deposit Products will earn a better yield than current deposits generally offered by commercial banks in the PRC while at the same time offer flexibility to the Group in terms of treasury management. Further, the Group has implemented adequate and appropriate internal control procedures to ensure the Subscriptions would not affect the working capital or the operations of the Group, and that such investments would be closely monitored and conducted in accordance with the Group's treasury policy. As such, the Board is of the view that the terms of the Structured Deposit Products are fair and reasonable, and are on normal commercial terms and the Subscriptions are in the interests of the Company and the Shareholders as a whole.

## **INFORMATION ABOUT THE PARTIES**

### **The Group**

The Group is a leading ophthalmic medical service group in North China with a strong reputation nationwide. As of the date of this announcement, the Group operated a network of 17 ophthalmic hospitals and 23 optical centers spanning across five provinces or autonomous region in China. The ophthalmic hospitals are specialized in providing ophthalmic services and the optical centers provide a series of optical products and services to satisfy a wide array of requests from customers.

### **BOC**

BOC is a joint stock company incorporated in the PRC with limited liability. BOC and its subsidiaries are principally engaged in the commercial banking business which provides services such as accepting deposits, making loans and offering basic investment products. BOC is listed on the Stock Exchange (Stock Code: 3988) and the Shanghai Stock Exchange (Stock Code: 601988).

As at the date of this announcement and to the best of the Director's knowledge, information and belief, having made all reasonable enquiries, BOC and their respective ultimate beneficial owners are third parties independent of the Company and its connected persons (as defined under the Listing Rules).

## **IMPLICATION UNDER THE LISTING RULES**

As each of the Structured Deposit Products was subscribed with the same bank within a 12 month period and is of a similar nature, they would be aggregated as if the Subscriptions were one transaction with that bank for the purpose of calculating the relevant percentage ratios pursuant to Rule 14.22 of the Listing Rules. As the highest applicable ratio of the Subscriptions, on an aggregate basis, exceeds 5% but is less than 25%, the Subscriptions constitute discloseable transactions of the Company and are hence subject to the reporting and announcement requirements but are exempted from the circular and Shareholders' approval requirements under Chapter 14 of the Listing Rules.

## **UTILISATION OF CERTAIN IDLE PROCEEDS RAISED FROM GLOBAL OFFERING FOR TREASURY MANAGEMENT**

Reference is made to (1) the section headed "Future Plans and Use of Proceeds" in the Prospectus in relation to the use of proceeds raised from the Global Offering; and (2) the section headed "Proceeds From Global Offering And Its Utilisation" in the interim report of the Company published on September 23, 2021.

The net proceeds from the Global Offering received by the Company, after deduction of the underwriting fees and commissions and other expenses payable by the Company with the Global Offering, amounted to approximately HK\$1,599 million. As of the date of this announcement, the Group has accumulatively used approximately HK\$102.6 million in accordance with the intended purposes as stated in the Prospectus, of which the balance of

such proceeds is HK\$1,496.4 million. According to the expected timeline for utilisation of the proceeds from the Global Offering, the Group anticipates no substantial funding would be used in a short period of time and a large amount of proceeds from the Global Offering will be left idle.

With a view to enhancing the utilisation and efficiency of its idle IPO Proceeds, the Company may apply some of the idle IPO Proceeds to further subscribe for low-risk short-term wealth management products issued by reputable commercial banks similar to the Subscriptions in the PRC or Hong Kong in the future, thereby increasing the overall income of the Company while at the same time ensuring that the planned usage of IPO Proceeds will not be affected.

Having taken into consideration the normal operation funding needs and liquidity needs of the Group, the Board is of the view that the subscription of low-risk short term wealth management products could make a better use of the financial resources of the Company which are currently idle and generate a source of income to the Company. Therefore, the Board considers that such subscription of low-risk short term wealth management products will be in the interests of the Company and its Shareholders as a whole. The Company will continuously assess the planned usage of IPO Proceeds and publish further announcement(s) in accordance with the requirements of the Listing Rules as and when appropriate.

## **DEFINITIONS**

In this announcement, unless the context otherwise requires, the following words and expressions shall have the meaning ascribed to them below:

“Board”	the board of Directors
“BOC”	Bank of China Limited
“Chaoju Medical Technology”	Chaoju Medical Technology Co., Ltd.* (朝聚醫療科技有限公司), a limited liability company established under the laws of the PRC on November 16, 2015, an indirect wholly-owned subsidiary of our Company, formerly known as Chaoju Medical Technology Equity Co., Ltd.* (朝聚醫療科技股份有限公司)
“China” or the “PRC”	the People’s Republic of China, but for the purpose of this announcement and for geographical reference only, references herein to “China” and the “PRC” do not apply to Hong Kong, Macau and Taiwan
“Company” or “the Company”	Chaoju Eye Care Holdings Limited, an exempted company with limited liability incorporated under the laws of the Cayman Islands on May 19, 2020
“Director(s)”	director(s) of the Company
“Global Offering”	the Hong Kong Public Offering and the International Offering (both as defined in the Prospectus)

“Group” or “the Group”	the Company together with its subsidiaries
“HK\$”	Hong Kong dollars and cents respectively, the lawful currency of Hong Kong
“IPO Proceeds”	the proceeds obtained by the Company from the Global Offering
“Listing Rules”	the Rules Governing the Listing of Securities on the Stock Exchange, as amended or supplemented from time to time
“Prospectus”	the prospectus of the Company published on June 24, 2021
“RMB”	the lawful currency of the PRC
“Share(s)”	ordinary share(s) in the share capital of the Company with nominal value of HK\$0.00025 each
“Shareholder(s)”	holder(s) of the Shares
“Stock Exchange”	the Stock Exchange of Hong Kong Limited
“Structured Deposit Products”	the structured deposit products offered by BOC and subscribed by the Group, the details of which are set out in this announcement
“Subscription(s)”	subscription(s) of the Structured Deposit Products
“%”	per cent

By order of the Board  
**Chaoju Eye Care Holdings Limited**  
**ZHANG Bozhou**  
*Chairman*

Hong Kong, November 17, 2021

*As of the date of this announcement, the Board of Directors of the Company comprises Mr. ZHANG Bozhou as the chairman and executive Director; Ms. ZHANG Xiaoli, Mr. ZHANG Junfeng and Mr. ZHANG Guangdi as executive Directors; Mr. KE Xian, Mr. Richard Chen MAO, Mr. LI Zhen and Ms. ZHANG Wenwen as non-executive Directors; and Mr. HE Mingguang, Ms. GUO Hongyan, Mr. LI Jianbin and Mr. BAO Shan as independent non-executive Directors.*

\* *The English translation of the Chinese names denoted in this announcement is for illustration purposes only. Should there be any inconsistencies, the Chinese name shall prevail.*